NovoCure (NVCR) Common Equity (2014 - 2026)

NovoCure (NVCR) has reported Common Equity for 13 consecutive years, with $338.1 million the latest figure, recorded in Q2 2026.

• Quarterly Common Equity fell 3.25% year-over-year to $338.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $338.1 million (down 3.25% YoY) and the FY2025 annual result came in at $340.5 million, down 5.47% from the prior year.
• Common Equity improved to $338.1 million in Q2 2026 per NVCR's latest filing, from $330.7 million in the prior quarter.
• Over the last five years, Common Equity for NVCR reached as high as $445.4 million in Q3 2022 and fell as low as $330.7 million in Q1 2026.
• A 5-year average of $381.8 million and a median of $361.9 million in 2024 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2022 — Common Equity climbed 17.13% — and 2023, when it slipped 17.83%.
• Year by year, Common Equity stood at $441.2 million in 2022, then retreated by 17.83% to $362.5 million in 2023, then fell by 0.64% to $360.2 million in 2024, then decreased by 5.47% to $340.5 million in 2025, then declined by 0.7% to $338.1 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $338.1 million, $330.7 million, and $340.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.